Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Neogenomics | Vintage Vibes

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

On Friday, the District Court for the Middle District of North Carolina issued a ruling invalidating specific claims in two patents that Natera Inc. (NASDAQ:NTRA) asserted against NeoGenomics, Inc.'s (NASDAQ:NEO) v1.1 RaDaR test.

3 Hot Trades for Insiders, But Are They Good Buys for Investors?

3 Hot Trades for Insiders, But Are They Good Buys for Investors?

Insiders are buying Hudson Pacific Properties and NeoGenomics, but selling Carvana. These trends will likely continue in 2025.

It's Not Too Late to Jump on These Under-the-Radar Momentum Plays

It's Not Too Late to Jump on These Under-the-Radar Momentum Plays

These three stocks may fly under the radar, but their recent price increases could appeal to investors seeking a momentum play.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022

Analyst Ratings for NeoGenomics

Over the past 3 months, 10 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Analyst Ratings for NeoGenomics

Analysts have provided the following ratings for NeoGenomics (NASDAQ:NEO) within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

NeoGenomics: Q1 Earnings Insights

NeoGenomics: Q1 Earnings Insights

NeoGenomics (NASDAQ:NEO) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

NeoGenomics Stock Gets Downgrade After CEO Resigns And Other Negative Updates

NeoGenomics Stock Gets Downgrade After CEO Resigns And Other Negative Updates

NeoGenomics, Inc.

Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2022

Why NeoGenomics Stock Is Plunging Today

Why NeoGenomics Stock Is Plunging Today

NeoGenomics Inc's (NASDAQ:NEO) CEO Mark Mallon will step down as CEO and member of the Board, effective immediately. The Board has retained Russell Reynolds to search for the Company's next CEO The Board has appointed current Chair Lynn Tetrault, Esq. as Executive Chair and established an Interim Office of the CEO. Read…

10 Biggest Price Target Changes For Tuesday

10 Biggest Price Target Changes For Tuesday

BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading.

Where NeoGenomics Stands With Analysts

Where NeoGenomics Stands With Analysts

Over the past 3 months, 8 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia

Here's a roundup of top developments in the biotech space over the last 24 hours:

Get all your
news in one place.

100's of premium titles.
One news app.

NeoGenomics Earnings Perspective: Return On Capital Employed

NeoGenomics (NASDAQ:NEO) brought in sales totaling $125.73 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 105.22%, resulting in a loss of $41.76 million.

Recap: NeoGenomics Q4 Earnings

NeoGenomics (NASDAQ:NEO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings NeoGenomics reported in-line EPS of $-0.14 versus an estimate of $-0.14.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play